Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

September 30, 2027

Conditions
Metastatic Triple-Negative Breast Carcinoma
Interventions
DRUG

PD1+ TILs (NUMARZU-001) product infusion

"The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~* Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~* Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction)."

Trial Locations (4)

28041

RECRUITING

Hospital 12 de Octubre, Madrid

31008

RECRUITING

Clínica universidad de Navarra, Pamplona

08035

RECRUITING

Hospital Universitari Vall d'Hebrón, Barcelona

08036

RECRUITING

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors
collaborator

SOLTI Breast Cancer Research Group

OTHER

lead

Fundacio Clinic Barcelona

OTHER